$246.34
▼ -0.2% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Overview
52-week range
$124
$266
86% of range
Avg surprise (last 3)
-27.4%
Avg reaction (last 2)
-2.0%
50% positive
Latest IV / EM
26%
EM ±4.1% · $250 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $2.78 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $5.46 | $3.82 | +42.9% | +810.0% | +2.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $4.08 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-9.07 | $-6.47 | -40.2% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $0.60 | $3.96 | -84.8% | — | -5.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $3.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.49 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.23 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $2.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.52 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $1.04 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | — | $1.13B | $1.05B | $898M | — | $1.05B |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $248M | $337M | — | $58M | $-686M | $-56M | — | $260M |
| Net income | $193M | $293M | — | $251M | $-718M | $-92M | — | $215M |
| EPS (diluted) | $2.78 | $4.43 | — | $4.08 | $-11.74 | $-1.52 | — | $3.42 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M |
| Total current assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B |
| Total assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B |
| Long-term debt | $3.33B | $4.32B | $4.33B | $4.33B | $4.34B | $5.34B | $6.08B | $6.08B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B |